At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Pulmatrix, Inc. (NASDAQ: PULM) reports that enrollment is underway in the Company's European pilot bioequivalence study of PUR0200, a proprietary iSPERSE™ (Inhaled Small Particles Easily...
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at Biotech Showcase 2016 on Monday, January 11th at 2:30 pm PST (5:30 pm EST). A live webcast of the presentation may be accessed in...
What: Pulmatrix, Inc. (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix, Inc. (Nasdaq: PULM) announced that the Company's common stock has qualified for and will begin trading today on the Nasdaq Global Market. The trading symbol remains PULM. Prior to...
Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of...